Tuberous Sclerosis Complex (TSC) in Hyderabad: Drug-Resistant Epilepsy, Brain Tumour Surveillance, and the mTOR Inhibitor That Treats the Root Cause

Infantile spasms — sudden, brief, symmetrical jerking movements of the body that occur in clusters, typically in children between 3 and 12 months of age — are associated with Tuberous Sclerosis Complex in approximately 25–30% of cases. TSC is one of the most common identifiable causes of West syndrome (infantile spasms + hypsarrhythmia on EEG + developmental regression). At KIMS, any infant presenting with infantile spasms receives: urgent video-EEG, MRI brain with TSC protocol, skin examination under Wood's lamp for hypopigmented macules, echocardiogram for cardiac rhabdomyomas, and TSC genetic testing. If TSC is confirmed or strongly suspected, vigabatrin is the specific first-line drug for infantile spasms in TSC — it is more effective for this presentation than for infantile spasms from other causes. Early, prompt treatment of infantile spasms is critical: the longer they continue, the worse the developmental outcome. Please call 040-44885000 or 040-46324365 urgently if your infant is having these events.

Yes — TSC is one of the most important causes of drug-resistant epilepsy in children, and it is frequently not diagnosed until after years of failed antiseizure medications. The specific features to look for: white depigmented skin patches (check under a UV lamp or Wood's lamp — they glow brightly), small reddish pimple-like spots on the nose and cheeks (facial angiofibromas), a rough patch of skin on the lower back (shagreen patch), any family history of similar skin findings or seizures, and MRI brain showing cortical tubers (sometimes described on reports as “cortical signal abnormalities” or “tubers”). At KIMS, any child with drug-resistant epilepsy onset in the first two years of life who has not had a specific genetic or structural cause identified receives a TSC-specific clinical and imaging assessment. The diagnosis changes the treatment: vigabatrin, everolimus, and epilepsy surgery evaluation become relevant options. Call 040-44885000.

Not immediately, if it is small and stable — but it must be monitored very closely. Small SEGAs that are not growing and not causing symptoms are managed with observation and annual MRI at KIMS. The specific concern with SEGAs is their location: they sit at the foramen of Monro — the narrow passage through which cerebrospinal fluid drains from the lateral ventricles into the third ventricle. A SEGA that grows slowly without notice can suddenly obstruct this passage and cause acute hydrocephalus, with rapidly increasing intracranial pressure that is life-threatening. At KIMS, the surveillance programme includes annual volumetric MRI measurement of the SEGA, comparing it precisely to the previous scan. If the volume increases significantly (approximately 0.5cm³ per year or more), the options at KIMS are: (1) everolimus to reduce the SEGA volume and halt growth, which is the current standard when the SEGA is growing without acute obstruction; (2) surgical resection if everolimus fails or if acute hydrocephalus develops. Please ensure your child is enrolled in the KIMS SEGA surveillance programme. Call 040-44885000.

Everolimus (Votubia) is an mTOR inhibitor — it targets the TSC1/TSC2 signalling pathway that is the root cause of TSC. For drug-resistant TSC epilepsy, the EXIST-3 clinical trial showed approximately 28–40% of patients achieve a 50% or greater reduction in seizure frequency. Real-world long-term data shows that the response rate improves over time: approximately 47–58% of patients achieve this level of response at 1–2 years of continuous treatment. It is not a cure and does not eliminate seizures in all patients, but it provides meaningful additional seizure control on top of existing medications in many. The common side effects managed at KIMS: mouth sores (stomatitis) — treated with mouthwash and dose reduction; respiratory infections — monitor for fever; delayed wound healing; immunosuppression requiring avoidance of live vaccines during treatment; and rarely interstitial pneumonitis. Blood levels of everolimus are monitored monthly at KIMS (target trough 5–15 ng/mL) alongside full blood count, renal function, and LFTs. Please call 040-44885000 to arrange a KIMS everolimus treatment discussion.

The chest scan (high-resolution CT or HRCT) is to screen for Lymphangioleiomyomatosis (LAM) — a progressive cystic lung disease that occurs almost exclusively in women with TSC, typically presenting in adulthood. LAM is caused by the same mTOR pathway dysregulation as other TSC manifestations — smooth muscle cells proliferating abnormally in the lungs and destroying alveolar tissue, producing cysts and eventually progressive breathlessness. LAM rarely causes symptoms in late teenage years but HRCT screening at age 18–20 establishes a baseline. If LAM is found and progressing, sirolimus or everolimus can slow its progression significantly. Symptoms of established LAM include: progressive breathlessness on exertion (the most common presenting symptom), spontaneous pneumothorax (collapsed lung — presenting as sudden chest pain and breathlessness), and occasionally haemoptysis. Any of these symptoms in a woman with TSC should trigger immediate review at KIMS — call 040-44885000.

Yes — Autism Spectrum Disorder (ASD) is one of the most common features of TSC-Associated Neuropsychiatric Disorders (TAND). Approximately 25–50% of individuals with TSC have ASD — making TSC one of the most common single-gene causes of autism. The autism in TSC arises from the same mTOR pathway dysregulation that produces tubers and other TSC lesions — abnormal neuronal connectivity and synaptic function during brain development. At KIMS, every TSC child is formally assessed for autism using validated tools (M-CHAT for toddlers, ADOS-2 for older children), and the specific autism profile — social communication, repetitive behaviours, sensory sensitivities — is documented. Management at KIMS for TSC-autism includes: Applied Behaviour Analysis (ABA), Early Start Denver Model (ESDM) in younger children, and evidence-based speech and occupational therapy. Seizure control improvement (with vigabatrin, everolimus, or surgery) can sometimes improve autism features, as frequent seizures and interictal discharges contribute to social and communicative difficulties. Call 040-44885000.

The most likely explanation is a de novo (new) mutation — a mutation that arose in your child for the first time, not inherited from either parent. Approximately two-thirds of TSC cases arise from de novo mutations, which is why a negative family history does not exclude TSC. De novo mutations occur during the formation of the egg or sperm, or in early embryonic development. Your next child's risk depends on: (1) Whether either parent has gonadal mosaicism — a situation where a mutation exists in some but not all of a parent's reproductive cells without being present in their blood cells. This is present in approximately 10–15% of apparently de novo TSC cases and means the recurrence risk is higher than for a truly de novo event. (2) Standard genetics: if neither parent has the mutation in blood testing, the empirical recurrence risk for a sibling is approximately 1–2% (from mosaicism risk). Prenatal diagnosis for the next pregnancy is available through chorionic villus sampling once your child's specific TSC1 or TSC2 mutation is confirmed. Pre-implantation genetic diagnosis (PGD) via IVF is also an option. Please call 040-44885000 for a KIMS genetic counselling appointment.